Santen Pharmaceutical Co., Ltd. (SNPHF)
USD 10.53
(0.0%)
USD 10.53
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 35.15 Billion JPY | -2.9% |
| 2023 | 36.2 Billion JPY | 9.94% |
| 2022 | 32.93 Billion JPY | 224.58% |
| 2021 | 10.14 Billion JPY | -17.7% |
| 2020 | 12.32 Billion JPY | 203.42% |
| 2019 | 4.06 Billion JPY | -46.53% |
| 2018 | 7.59 Billion JPY | -55.12% |
| 2017 | 16.92 Billion JPY | -24.71% |
| 2016 | 22.48 Billion JPY | -39.43% |
| 2015 | 37.11 Billion JPY | 62811.86% |
| 2014 | 59 Million JPY | -32.18% |
| 2013 | 87 Million JPY | -24.35% |
| 2012 | 115 Million JPY | -24.34% |
| 2011 | 152 Million JPY | -75.36% |
| 2010 | 617 Million JPY | -11.6% |
| 2009 | 698 Million JPY | -86.78% |
| 2008 | 5.27 Billion JPY | -3.08% |
| 2007 | 5.44 Billion JPY | -2.99% |
| 2006 | 5.61 Billion JPY | -18.42% |
| 2005 | 6.88 Billion JPY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 34.69 Billion JPY | -4.19% |
| 2024 Q4 | 35.15 Billion JPY | 4.57% |
| 2024 FY | 35.15 Billion JPY | -2.9% |
| 2024 Q3 | 33.62 Billion JPY | -0.82% |
| 2024 Q2 | 33.9 Billion JPY | -2.28% |
| 2023 Q3 | 37.09 Billion JPY | -2.71% |
| 2023 Q2 | 38.12 Billion JPY | 70.95% |
| 2023 FY | 36.2 Billion JPY | 9.94% |
| 2023 Q4 | 36.2 Billion JPY | -2.39% |
| 2023 Q1 | 22.3 Billion JPY | -32.28% |
| 2022 Q3 | 21.22 Billion JPY | 6.56% |
| 2022 Q1 | 10.04 Billion JPY | -1.0% |
| 2022 Q2 | 19.91 Billion JPY | 98.26% |
| 2022 Q4 | 32.93 Billion JPY | 55.18% |
| 2022 FY | 32.93 Billion JPY | 224.58% |
| 2021 FY | 10.14 Billion JPY | -17.7% |
| 2021 Q1 | - JPY | -100.0% |
| 2021 Q2 | - JPY | 0.0% |
| 2021 Q3 | - JPY | 0.0% |
| 2021 Q4 | 10.14 Billion JPY | 0.0% |
| 2020 Q3 | - JPY | 0.0% |
| 2020 Q2 | - JPY | 0.0% |
| 2020 FY | 12.32 Billion JPY | 203.42% |
| 2020 Q1 | - JPY | -100.0% |
| 2020 Q4 | 9.6 Billion JPY | 0.0% |
| 2019 Q2 | - JPY | 0.0% |
| 2019 Q4 | 4.06 Billion JPY | 0.0% |
| 2019 Q3 | - JPY | 0.0% |
| 2019 FY | 4.06 Billion JPY | -46.53% |
| 2019 Q1 | - JPY | -100.0% |
| 2018 Q2 | - JPY | 0.0% |
| 2018 FY | 7.59 Billion JPY | -55.12% |
| 2018 Q4 | 7.59 Billion JPY | 0.0% |
| 2018 Q3 | - JPY | 0.0% |
| 2018 Q1 | - JPY | -100.0% |
| 2017 Q1 | - JPY | -100.0% |
| 2017 FY | 16.92 Billion JPY | -24.71% |
| 2017 Q4 | 16.95 Billion JPY | 0.0% |
| 2017 Q3 | - JPY | 0.0% |
| 2017 Q2 | - JPY | 0.0% |
| 2016 Q2 | - JPY | 0.0% |
| 2016 Q1 | - JPY | -100.0% |
| 2016 FY | 22.48 Billion JPY | -39.43% |
| 2016 Q4 | 22.46 Billion JPY | 0.0% |
| 2016 Q3 | - JPY | 0.0% |
| 2015 Q3 | 40.08 Billion JPY | 14.34% |
| 2015 Q4 | 37.11 Billion JPY | -7.41% |
| 2015 FY | 37.11 Billion JPY | 62811.86% |
| 2015 Q1 | 35.07 Billion JPY | 59352.54% |
| 2015 Q2 | 35.06 Billion JPY | -0.05% |
| 2014 FY | 59 Million JPY | -32.18% |
| 2014 Q4 | 59 Million JPY | -6.35% |
| 2014 Q3 | 63 Million JPY | -11.27% |
| 2014 Q2 | 71 Million JPY | -13.41% |
| 2014 Q1 | 82 Million JPY | -5.75% |
| 2013 FY | 87 Million JPY | -24.35% |
| 2013 Q4 | 87 Million JPY | 0.0% |
| 2013 Q2 | - JPY | 0.0% |
| 2013 Q3 | - JPY | 0.0% |
| 2013 Q1 | - JPY | -100.0% |
| 2012 Q4 | 115 Million JPY | 0.0% |
| 2012 Q3 | - JPY | 0.0% |
| 2012 Q2 | - JPY | 0.0% |
| 2012 Q1 | - JPY | -100.0% |
| 2012 FY | 115 Million JPY | -24.34% |
| 2011 Q3 | - JPY | -100.0% |
| 2011 FY | 152 Million JPY | -75.36% |
| 2011 Q1 | 544 Million JPY | -11.83% |
| 2011 Q2 | 260 Million JPY | -52.21% |
| 2011 Q4 | 152 Million JPY | 0.0% |
| 2010 Q3 | 765 Million JPY | -9.04% |
| 2010 FY | 617 Million JPY | -11.6% |
| 2010 Q2 | 841 Million JPY | 0.0% |
| 2010 Q4 | 617 Million JPY | -19.35% |
| 2009 Q4 | 698 Million JPY | 0.0% |
| 2009 FY | 698 Million JPY | -86.78% |
| 2008 FY | 5.27 Billion JPY | -3.08% |
| 2007 FY | 5.44 Billion JPY | -2.99% |
| 2006 FY | 5.61 Billion JPY | -18.42% |
| 2005 FY | 6.88 Billion JPY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AstraZeneca PLC | 28.58 Billion USD | -23.009% |
| Bristol-Myers Squibb Company PFD CONV 2 | 41.46 Billion USD | 15.208% |
| CSPC Pharmaceutical Group Limited | 99.64 Million USD | -35182.91% |
| Clarus Therapeutics Holdings, Inc. | 42.26 Million USD | -83076.796% |
| Novartis AG | 26.34 Billion USD | -33.437% |
| PT Kalbe Farma Tbk. | 40.4 Million USD | -86912.338% |